Study on Tuberous Sclerosis Treatment Timing and Drug Effectiveness
Author Information
Author(s): Michael P Messina, Aubrey Rauktys, Laifong Lee, Sandra L Dabora
Primary Institution: Brigham & Women's Hospital
Hypothesis
Does the timing of treatment with CCI-779 and interferon-gamma affect the severity of kidney lesions in Tsc2+/- mice?
Conclusion
The presence of growing tumors is crucial for effective treatment, and rapamycin is more effective than CCI-779 in reducing tumor growth.
Supporting Evidence
- Treatment with CCI-779 or CCI-779 plus IFN-γ reduced kidney tumor burden in Tsc2+/- mice.
- No significant difference was observed between treatment at 6–8 months versus 10–12 months.
- Rapamycin was found to be more effective than CCI-779 in reducing tumor growth and improving survival.
Takeaway
If you want to treat kidney problems in mice with a disease called Tuberous Sclerosis, it's better to start treatment when the tumors are already growing, and one medicine works better than another.
Methodology
Tsc2+/- mice were treated with CCI-779 or a combination of CCI-779 and IFN-γ at different ages, and kidney disease severity was evaluated using quantitative histopathology.
Potential Biases
Potential bias due to the use of sibling littermates as controls.
Limitations
The study did not include a group treated with single agent IFN-γ, and the treatment duration for IFN-γ was shorter than in previous studies.
Participant Demographics
Tsc2+/- mice, including both male and female subjects.
Statistical Information
P-Value
0.03
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website